-
Tytuł:
-
Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison.
-
Autorzy:
-
Cholette F; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Mesa C; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Harris A; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Ellis H; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Cachero K; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Lacap P; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Galipeau Y; Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.
Langlois MA; Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.; The Centre for Infection, Immunity, and Inflammation (CI3), University of Ottawa, Ottawa, Canada.
Gingras AC; Department of Molecular Genetics, University of Toronto, Toronto, Canada.; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Canada.
Yansouni CP; McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.
Papenburg J; McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.; Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montréal-McGill University Health Centre, Montréal, Canada.
Cheng MP; McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, Canada.; Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montréal-McGill University Health Centre, Montréal, Canada.
Chakraborty P; Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Stein DR; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.; Cadham Provincial Laboratory, Manitoba Health, Winnipeg, Canada.
Van Caeseele P; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.; Cadham Provincial Laboratory, Manitoba Health, Winnipeg, Canada.; Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Canada.; COVID-19 Immunity Task Force, Montréal, Canada.
Bartlett S; British Columbia Centre for Disease Control, Vancouver, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Krajden M; British Columbia Centre for Disease Control, Vancouver, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Goldfarb D; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
McGeer A; COVID-19 Immunity Task Force, Montréal, Canada.; Division of Infectious Diseases, University of Toronto, Toronto, Canada.
Osiowy C; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Hankins C; COVID-19 Immunity Task Force, Montréal, Canada.; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Canada.
Mazer B; Department of Pediatrics, McGill University, Montréal, Canada.
Drebot M; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Kim J; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
-
Corporate Authors:
-
COVID-19 Immunity Task Force (CITF) working group
-
Źródło:
-
PloS one [PLoS One] 2021 Dec 07; Vol. 16 (12), pp. e0261003. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021).
-
Typ publikacji:
-
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Dried Blood Spot Testing*
Antibodies, Viral/*blood
COVID-19/*diagnosis
COVID-19 Testing/*methods
Area Under Curve ; COVID-19/virology ; Humans ; ROC Curve ; Reagent Kits, Diagnostic ; SARS-CoV-2/isolation & purification ; Sensitivity and Specificity
-
References:
-
Arch Pathol Lab Med. 2021 Jan 1;145(1):32-38. (PMID: 33367664)
Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876)
Nat Biotechnol. 2020 Oct;38(10):1174-1183. (PMID: 32855547)
Microorganisms. 2021 Jan 25;9(2):. (PMID: 33504067)
JCI Insight. 2020 Oct 2;5(19):. (PMID: 32870820)
J Clin Microbiol. 2020 Dec 17;59(1):. (PMID: 33023911)
NPJ Digit Med. 2020 Jul 13;3:95. (PMID: 32695885)
J Clin Microbiol. 2020 Jul 23;58(8):. (PMID: 32341142)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
J Clin Virol. 2020 Jul;128:104426. (PMID: 32417674)
Am J Clin Pathol. 2020 Oct 13;154(5):610-619. (PMID: 32808976)
CMAJ. 2020 Aug 24;192(34):E973-E979. (PMID: 32753391)
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652. (PMID: 32584464)
Emerg Infect Dis. 2020 Dec;26(12):2970-2973. (PMID: 32969788)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
Sci Rep. 2020 Nov 19;10(1):20188. (PMID: 33214612)
Lancet Infect Dis. 2020 Dec;20(12):1390-1400. (PMID: 32979318)
Sci Rep. 2021 Apr 8;11(1):7754. (PMID: 33833246)
Nat Med. 2021 Jan;27(1):28-33. (PMID: 33442016)
BMC Med. 2020 Nov 4;18(1):346. (PMID: 33143712)
Cell Rep Med. 2020 Aug 25;1(5):100062. (PMID: 32838340)
AAPS J. 2020 Oct 6;22(6):127. (PMID: 33025311)
Sci Rep. 2021 May 4;11(1):9475. (PMID: 33947894)
PLoS One. 2020 Nov 9;15(11):e0241959. (PMID: 33166373)
Lancet. 2020 Apr 4;395(10230):1101-1102. (PMID: 32247384)
EJIFCC. 2009 Jan 20;19(4):203-11. (PMID: 27683318)
Clin Chim Acta. 2020 Oct;509:1-7. (PMID: 32485157)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
Lancet. 2020 May 2;395(10234):e79-e80. (PMID: 32334649)
Nat Commun. 2021 Mar 22;12(1):1813. (PMID: 33753738)
-
Substance Nomenclature:
-
0 (Antibodies, Viral)
0 (Reagent Kits, Diagnostic)
-
Entry Date(s):
-
Date Created: 20211207 Date Completed: 20211215 Latest Revision: 20211215
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8651133
-
DOI:
-
10.1371/journal.pone.0261003
-
PMID:
-
34874948
-
The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19.
Competing Interests: The authors have declared that no competing interests exist.
